Drug Database
Back to search

Belgium· BE-AMP-SAM501644-00

Abacavir/Lamivudine Mylan 600 mg - 300 mg

A lamivudine and abacavir product containing lamivudine, registered in Belgium by Viatris GX. The same ATC class is registered in 14 of our 19 countries.

ATC J05AR02

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedAbacavir/Lamivudine Mylan 600 mg - 30…ATCJ05AR02REGISTER NO.BE-AMP-SAM501644-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lamivudineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lamivudine and abacavir is registered in 14 of 19 countries.

Countries holding a registration under ATC J05AR02 (lamivudine and abacavir), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose
Search lamivudine and abacavir products by name

Lamivudine and abacavir · ATC J05AR02

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Lamivudine
Manufacturer
Viatris GX
Country
Belgium (BE)
ATC code
J05AR02
ATC class
Lamivudine and abacavir
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    3533122
  • be_apb
    7718331

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for lamivudine and abacavir.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lamivudine and abacavir against other medicinesHow interaction checks work

Lamivudine and abacavir · interactions on record

2 records

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Lamivudine and abacavir in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lamivudine and abacavir products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Austria · Lamivudin Sandoz
  • Cyprus · Lamivudine Normon
  • Germany · Lamivudin Aurobindo, Lamivudin Mylan
  • Spain · Lamivudina Accord, Lamivudina Aurovitas
  • France · Lamivudine Arrow, Lamivudine Sandoz
  • United Kingdom (Northern Ireland) · Lamivudine Amarox, Lamivudine Generics
  • Iceland · Epivir, Lamivudine Teva
  • Italy · Lamivudina Aurobindo, Lamivudina Aurobindo Italia
  • Liechtenstein · Epivir, Lamivudine Teva
  • Netherlands · Lamivudine Accord, Lamivudine Aurobindo
  • Norway · Epivir, Lamivudine Teva
  • Poland · Lamivudine Aurovitas
  • Portugal · Lamivudina Aurobindo, Lamivudina Farmoz

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4d10acc6-3bb5-4947-96e8-6ea8170091a5
GET /v1/drugs/4d10acc6-3bb5-4947-96e8-6ea8170091a5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "Abacavir/Lamivudine Mylan 600 mg - 300 mg",
  "name_fr": "Abacavir/Lamivudine Mylan 600 mg - 300 mg",
  "name_nl": "Abacavir/Lamivudine Mylan 600 mg - 300 mg",
  "amp_code": "SAM501644-00",
  "strengths": [
    "300.0000",
    "300.0000",
    "676.4010",
    "676.4010",
    "600.0000",
    "600.0000",
    "300.0000",
    "300.0000",
    "676.4010",
    "676.4010",
    "600.0000"
  ],
  "pack_count": 8,
  "substances": [
    "Lamivudine",
    "Abacavir Hydrochloride",
    "Abacavir",
    "E 110 Lacquer",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Lamivudine and Abacavir",
  "authorisation_numbers": [
    "BE501644",
    "BE501653"
  ]
}
API referenceMCP serverPlans

See everything about lamivudine and abacavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console